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Abstract  
BACKGROUND: Renal transplantation (RTx) is the treatment of choice for paediatric end-stage renal disease 
(ESRD). A major cause of morbidity and mortality after RTx is cardiovascular disease. Independent predictors of 
cardiovascular events were shown to constitute an endothelial dysfunction (ED). This study aims to evaluate 
Visfatin serum level in comparison to brachial artery flow-mediated dilatation (FMD) as a marker of endothelial 
dysfunction in paediatric RTx recipients.
 
METHODS: Visfatin serum level has been evaluated in 30 patients on regular hemodialysis (HD), 36 patients 
post-RTx and 30 controls as a measure for ED, and has been compared to brachial artery FMD. 
 
RESULTS: Visfatin level in transplant recipients was significantly lower than the hemodialysis group as well as 
FMD was better in transplant recipients. In spite of marked improvement of FMD and marked reduction of visfatin 
in post-RTx no direct statistical correlation was found between serum Visfatin level and flow-mediated dilatation.  
CONCLUSION: Pediatric RTx recipients show lower serum Visfatin level and better FMD than those on regular 
hemodialysis, reflecting less endothelial dysfunction (ED) and less cardiovascular risk. FMD in kidney transplant 
recipients tends to be less than normal subjects while visfatin level of the same group is similar to controls. 
Pediatric RTx appears to have a positive impact on the growth development of children with ESRD. 
 
 
 
 
 
 
 
 
 
Introduction 
 
The endothelium plays a central role in the 
control of many aspects of vascular function. It 
responds to changes in blood-borne signals and 
hemodynamic forces by releasing vasoactive 
substances such as nitric oxide (NO). Endothelial 
dysfunction may result from decreased production or 
availability of NO [1] endothelial dysfunction (ED). It is 
now generally accepted that the first step in 
atherosclerosis [2] ED appears to be useful in the 
prediction of morbidity and mortality in cardiovascular 
risk groups [3].  
Mortality from cardiovascular events and ED 
has been studied in adults and children with CKD [4]. 
Cardiovascular disease still represents a major cause 
of morbidity and mortality after kidney transplantation 
in spite of successful renal transplantation is 
associated with the elimination of uremia and 
consequently would be expected to improve ED [5]. 
Visfatin, also known as a pre-B-cell colony-enhancing 
factor (PBEF), is a novel and ubiquitous adipokine 
secreted by various tissues, especially visceral and 
subcutaneous fat [6]. Several clinical studies have 
shown a positive correlation between endothelial 
dysfunction and enhanced visfatin plasma levels [7]. 
Alternative markers of endothelial damage in CKD 
stage 5 patients have been positively associated with 
increased plasma visfatin levels [8]. 
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The aim of this work was to study plasma 
visfatin level in paediatric kidney transplant recipients, 
in comparison to those on regular HD as well as 
normal children and to determine the relation between 
plasma Visfatin level and flow- mediated dilatation and 
other risk factors for endothelial dysfunction in 
paediatric renal transplant recipients. 
 
 
 
Subjects and Methods 
  
This is a cross-sectional study that included 
96 paediatric subjects in three groups (36 post-renal 
transplantations for more than 12 months, 30 on 
regular hemodialysis for more than 3months, 30 
normal children as controls). 
We exclude from the study children 
presenting with acute problems associated with 
infection or inflammation and transplanted children 
with moderate or severe chronic graft dysfunction 
(eGFR < 45 mL/min/1.73 m^2). Also, patients with DM 
were excluded from our study.  
Patients were recruited from Center of 
Pediatric Nephrology and Transplantation Unit, 
paediatric hospital, Kasr El Aini Faculty of Medicine, 
Cairo University. Control subjects were healthy age 
and sex matched relatives of cases attending the 
outpatient general clinic for acute illness. 
 
Informed consent was obtained from the legal 
guardians of the patients before enrollment in the 
study. The study protocol was approved by the 
Research Committee of Pediatric Department, Faculty 
of Medicine, and Cairo University.  
All patients were subjected to the following:  
1. Detailed history: focusing on; Age of 
diagnosis, the cause of renal failure, duration of 
follow-up, onset and duration of renal replacement 
therapy, associated problems, hypertension, 
medications used, complications met, family history 
including consanguinity and similar conditions. 
 
2. Full clinical examination: stressing on;  
a. Anthropometric measurements including 
Height and weight were calculated as a percent of the 
median for age and sex to be corrected for age-
related difference. Body mass index (BMI) was 
calculated from the formula: BMI=weight in kg/ square 
the height in meter. 
 
b. Vital signs especially heart rate and blood 
pressure.  
Blood pressure percentiles were determined 
according to (Bernstein, 2011) [9], and BP was 
classified into i. Normal BP: <90 percentile with no 
antihypertensive medications; ii. Borderline 
hypertension: BP between 90-95th percentile without 
antihypertensive; iii. Controlled Hypertension: BP < 
95th percentile on treatment; and iv. Uncontrolled 
Hypertension: BP ≥ 95th percentile with treatment.  
3. For transplant patients: Review of early 
graft function, the occurrence of acute rejection 
episodes, immunosuppressive regimen and steroid 
doses, patient compliance as well as the presence of 
hypertension, anaemia, graft dysfunction or other 
problems. 
 
4. Routine laboratory investigations: CBC, 
BUN, serum creatinine level, Serum electrolytes 
including potassium, sodium, calcium and phosphorus 
levels, fasting blood glucose and lipid profile including 
cholesterol level, HDL, LDL and triglycerides, Liver 
function tests including ALT, ALP, total bilirubin level 
and serum albumin.  
5. Glomerular filtration rate (GFR) calculated 
from serum creatinine using the Schwartz formula [10] 
in transplanted children and assessment of delivered 
dialysis dose using fractional urea clearance 
measured by single pool KT/v [11] in dialysis patients.  
6. Assessment of Brachial artery flow-
mediated dilatation by Doppler.  
- It was measured by the comparison between 
the vessel diameter at rest with that during reactive 
hyperemia. 
 
- The diameter of the brachial artery was 
imaged above the antecubital fossa in the longitudinal 
plane. Arterial flow velocity was measured with a 
pulsed Doppler signal at a 90° angle to the vessel.  
- A baseline scan was taken after the patient 
had an initial rest period of 15 min in the supine 
position. To induce increased flow, the pneumatic 
tourniquet was applied to the forearm and inflated to a 
pressure above the systolic blood pressure for 5 min, 
then released. 
 
- The second scan for reactive hyperemia was 
taken continuously from 30 s before to 90 s after cuff 
deflation, with flow velocity recording for the first 30 s 
following cuff deflation. 
 
- Resting and peak flow volumes (ml/min) 
were measured.  
- Reactive hyperemia (RH) was calculated as 
follows: RH = (Peak flow/resting flow) ×100.  
- Percent flow-mediated dilatation (FMD %) 
represented the difference between vessel diameter 
at rest (D1) and during reactive hyperemia (D2) was 
calculated as follows:  
FMD = (D2 - D1 / D1) X 100 
A percent FMD less than 5% was considered 
impaired.  
7. Echocardiography to asses' cardiac 
function in both group. 
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8. Measurement of plasma Visfatin level 
(using ELISA technique) for cases and controls: 
Steps: i. Serum was left to coagulate at room 
temperature for 10-20 minutes then centrifuged for 20 
minutes at the speed of 2000-3000 round per minute; 
then the supernatant was removed; ii. Ten standard 
wells were set on the ELISA coated plates. Standard 
100μl were added to the first and the second wells, 
then standard dilution of 50 μl was added to the first 
and second wells, mixed, then 100 μl were taken out 
of the first and second well then added to the third and 
fourth well separately, then standard dilution of 50 μl 
was added to the third and fourth wells, mixed, 50 μl 
were taken out from the third and fourth wells and 
discarded. 50 μl were added to the fifth and the sixth 
wells, then standard dilution 50 μl added to the fifth 
and the sixth wells, mixed, 50 μl taken out from the 
fifth and sixth wells and added to the seventh and the 
eighth wells, then standard dilution of 50 μl added to 
the seventh and eighth wells, mixed, 50 μl taken out 
from the seventh and eighth wells and added to the 
ninth and the tenth wells then standard dilution of 50 
μl added to the ninth and the tenth well, mixed, 50 μl 
taken out from the ninth and the tenth well and 
discarded (a sample 50 μl was added to each well 
after diluting ) (density 18 μg/l, 12 μg/l, 6 μg/l, 3 μg/l, 
1.5 μg/l); iii. Blank wells were set separately (we didn’t 
add sample and HRP-conjugate reagent in blank 
comparison wells; other operation steps are carried 
out the same). We added sample dilution of 40 μl to 
the testing sample well, then added another testing 
sample of 10 μl (sample final dilution is 5-fold), trying 
not to touch the well as far as possible, and gently 
mixed; iv. Then we closed the plate with the closure 
plate membrane, and incubated for 30 minutes at 
37
0
C; v. A 30 fold wash solution was diluted 30 fold 
with distilled water and reserved; vi. We uncovered 
the closure plate membrane, discarded liquid, dried by 
swing, added washing buffer to every well, waited for 
30 s then drained, repeated 5 times, dried by Pat; vii. 
Then we added HRP-conjugate reagent 50 μl to each 
well except the blank well; viii. We repeated step iv 
again followed by step vi again; ix. Then we added 
chromogen solution A 50 μl and chromogen solution B 
to each well, evaded the light preservation for 15 
minutes at 37
0
C; x. We added sulphuric acid stop 
solution 50 μl to each well, till the blue colour changed 
to yellow; xi. We considered a blank well as zero, and 
then read absorbance spectrophotometrically at 450 
nm within 15 minutes from adding the stop solution; 
and xii. We took the standard density as the 
horizontal, the OD value for the vertical, then we 
plotted the standard curve on a graph paper, then we 
had to find out the corresponding density according to 
the sample OD value by the sample curve, multiplied 
by the dilution multiple, or we sometimes calculated 
the straight-line regression equation of the standard 
curve with the standard density and the OD value. 
Using with the sample OD value in the equation, we 
calculated the sample density, multiplied by the 
dilution factor to get the actual sample density. 
 
Analysis of data 
Data were tabulated and subjected to 
computer-assisted statistical analysis using Microsoft 
Excel version 2003 and the Statistical Package for 
Social Science (SPSS) for Windows version 16.0. 
Nominal data were expressed as frequency and 
percentage and were compared using chi- squared 
tests. Numerical data were expressed as a mean and 
standard deviation and were compared using 
independent samples t-tests. P Values less than 0.05 
were considered significant.
 
 
 
Results 
 
Ninety-six paediatric subjects were included in 
this study (36 post-RTx for more than 12 months, 30 
on HD for more than 3 months, and 30 normal 
children as controls). Twenty-six (87%) of 
hemodialysis group were on HD for more than one 
year Regarding transplantation 29 paediatric patients 
transplanted from related living donor only 7patients 
19.4% from unrelated living donor 
 
Overall, the study groups consist of 50 males 
52% and 46 females 48%. Clinical data of the study 
group was showed in Table 1. 
Table 1: Clinical data of transplant recipients and hemodialysis 
patients 
 Transplant recipients 
(n = 36) 
(mean ± SD) 
Hemodialysis patients 
(n = 30) 
(mean ± SD) 
P value 
Age (years) 11.5 ± 3.48 11.4 ± 3.34 0.93 
Weight (kg) 32.83 ± 14.77 24.54 ± 9.43 0.008 
Weight (% median) 
 
80.3 ± 22.09 61.2 ± 20.8 0.0006 
Height (cm) 123.25 ± 14.03 117.03 ± 13.99 0.08 
Height (%median) 85.6 ± 5.8 80.4 ± 7.7 0.003 
SBP (mmHg) 109 ± 10.5 113 ± 13.3 0.13 
DBP (mmHg) 70.28 ± 8.45 72.63 ± 7.52 0.24 
BMI (kg/m2) 20.76 ± 6.26 17.50 ± 4.11 0.014 
SBP: systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index. 
 
The most common cause of renal failure of 
both groups was urological abnormalities followed by 
undetermined cause as illustrated in Table 2.  
Table 2: Aetiology of renal disease in transplant and dialysis 
groups (n=66)
 
 All cases D T 
 No % No % No % 
CAKUT 20 30.30 8 26.67 12 33.33 
PUJO 1 1.52 1 3.33 0 0 
PUV 11 16.67 5 16.67 6 16.67 
Urolithiasis 1 1.515 0 0 1 2.78 
Reflux nephropathy 7 10.61 2 6.67 5 13.89 
Undetermined 17 25.76 9 30 8 22.22 
Primary glomerulopathy
 7 10.6 4 13.33 3 8.33 
NPHP 13 19.69 5 16.67 8 22.22 
PKD 2 3.03 0 0 2 5.56 
Oxalosis 2 3.03 1 3.33 1 2.78 
Cystinosis 2 3.03 1 3.33 1 2.78 
HUS 1 1.52 1 3.33 0 0 
Chronic interstitial nephritis 2 3.03 1 3.33 1 2.78 
CAKUT (congenital anomalies of the kidney and urinary tract); PUJO (periureteric junction 
obstruction); PUV (posterior urethral valve), NPHP (nephronophthisis); PKD (polycystic 
kidney disease), HUS (hemolytic uremic syndrome). 
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Regarding Echocardiography of studied 
patients at the time of assessment, we found no 
significant difference between both groups regarding 
FS. LVEDD (cm/m2) tended to be higher in dialysis 
group (p=0.057). 
FMD of transplanted and dialysis groups 
versus control group showed in Fig. 1. 
  
Figure 1: Flow- mediated dilatation (FMD) of the three studied 
groups (n = 96). T = transplanted; D = dialysis; C = control 
 
As illustrated by Fig. 1, the resting and peak 
flow volumes were somewhat lower in the dialysis 
group than the transplanted group.  
In comparison to the control group- the post 
RTx patients showed almost similar serum visfatin 
level (median IQR of 4 (3.5-5.8)) to the control group 
while in patients on dialysis the median visfatin level is 
almost 15 times the control group (median (IQR) 
65(30-70) ng/ml, and it was statistically significant p < 
0.0001 as showed in Fig. 2. 
 
Figure 2: Visfatin level in the three groups ng/ml. T = transplanted; 
D = dialysis; C = control 
 
Inspite marked improvement of FMD and 
reduction of serum visfatin level There was no 
significant correlation between serum visfatin and 
FMD; whether as an absolute value (r= -0.15, p = 
0.28) or the FMD% (r = -0.10, p = 0.47).  
Among clinical data obtained, significant 
positive correlation between duration of dialysis) and 
serum visfatin level (r = 0.56, p = 0.00001) and also 
there is negative non-significant correlation (r =            
-0.102, p = 0.56). 
Among laboratory data obtained, significant 
correlations were found mainly between serum 
alkaline phosphatase, triglycerides level (TG) and 
serum visfatin level (r = 0.31, p = 0.027), (r = 0.49, p = 
0.0006) respectivly. 
 
 
Discussion 
 
The burden of chronic disease throughout the 
world is steadily increasing. Cardiovascular disease 
(CVD) and chronic kidney disease (CKD) frequently 
coexist and represent a major challenge in today’s 
medicine [12]. The aim of this study was to study 
plasma Visfatin level in paediatric RTx recipients, in 
comparison to those on regular HD as well as normal 
children and to determine the relation between plasma 
Visfatin level and FMD and other risk factors for 
endothelial dysfunction in RTx recipients and HD 
patients.
 
The mean age of our transplant recipients 
was similar to that of the dialysis group. Preemptive 
transplantation was undertaken in 11 of 36 transplant 
recipients, while the others were transplanted after a 
mean period of 21.6 months on dialysis. Transplant 
recipients predictably had shorter dialysis duration 
than the HD group (mean 52.2 months).  
Among our 36 patients who were recipients of 
RTx, the source was a living donor in 100% of cases, 
which is mainly due to the Egyptian regulations 
governing the transplantation procedures in Egypt. 
 
Living donors' allografts are favoured over 
those from deceased donors; Rockville 2010 found 
that the five-year survival for the allografts is greater in 
the former according to the NAPRTCS data [13]. 
In the aetiology of ESRD in the studied 
groups, the leading causes were CAKUT by 33.3% 
and 26.6%, of the transplanted and the dialysis 
groups respectively. Second, an undetermined cause 
which affected almost 22.2% and 30% of the 
transplanted and the dialysis groups respectively. 
These kidney pathologies resemble those in the 
NAPRTCS 2010 transplant and 2011 dialysis report; 
where CAKUT (obstructive uropathies 15.3% and 
12.6%, then reflux nephropathy 5.2% and 3.5%, 
congenital renal aplasia/dysplasia 15.8% and 14.2% 
of the transplanted and the dialysis groups 
respectively). Cystic pathologies 5.7% and 4.9%, 
Focal segmental glomerulosclerosis 11.7% and 14.4% 
transplanted and the dialysis groups respectively were 
also leading causes. 
 
Hypertension is a common complication 
following RTx in children and considers being a risk 
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factor for increased cardiovascular morbidity and 
grafting failure [14]. In our study, there is a positive 
correlation between visfatin and hypertension but 
statistically not significant.  
RTX group has significantly lower systolic and 
diastolic blood pressure than dialysis group (p = 0.02) 
at 90th centile, and a significantly lower diastolic blood 
pressure (p = 0.04) at the 95th centile. 
Considering variables related to endothelial 
dysfunction the control subjects had mean FMD (%) of 
16.13 The mean FMD (%) in dialysis patients was 7.6, 
significantly lower than normal subjects (16.1%; p < 
0.001). This denotes that children with ESRD on HD 
have ED manifested as impaired endothelium-
dependent VD.  
RTx recipients in our study, they had a mean 
FMD of 12%; significantly better than dialysis patients 
(p = 0.04). They also tended to have lower FMD than 
normal subjects, with a difference not reaching 
statistical significance (p = 0.08). 
Regarding serum visfatin level, the median 
serum visfatin in normal subjects was 5 ng/ml (IQR 
2.4-6 ng/ml). HD patients had significantly higher 
level; with more than 10 folds of normal controls. This 
in agree with the study was done on 68 patients on 
HD patients compared with 22 healthy controls, 
showed a highly significant increase in serum visfatin 
in the CKD group on HD in comparison with the 
healthy control participants [15].  
In RTx recipients the median serum visfatin 
was significantly lower than dialysis patients and near 
to normal subjects. This in agree with an adult study 
was done to measured visfatin levels in 58 living 
donor kidney transplant non-diabetic recipients, before 
transplantation and on the 30th and 90th day after 
transplantation [16]. 
The authors are aware of the relation between 
visfatin levels & glomerular filtration rate (GFR), 
possibly independently of ED; however, since patients 
on regular HD & RTx recipients with stable graft 
function each reflect essentially the same level of 
renal function, this is not expected to confound results 
significantly.  
In our study, we couldn’t find a significant 
statistical correlation between serum visfatin and 
FMD; whether as an absolute value (r = -0.15, p = 
0.28) or the FMD% (r = -0.10, p = 0.47). In our 
paediatric Rtx visfatin and FMD are near normal 
subjects. Therefore, the lack of statistically significant 
correlation can't rule out the presence of such 
correlations in populations with marked endothelial 
dysfunction such as dialysis patients. Dyslipidemia is 
an established risk factor for atherosclerosis in uremic 
and numeric patients [17]. Among laboratory data 
obtained, significant correlations were found mainly 
between serum triglycerides and visfatin serum level 
(r = 0.49, p = 0.0006). The similar positive correlation 
was found by others [7, 15]. 
Whether the significant lowering in visfatin 
level post RTx in comparison to HD, could be a cause 
or a marker for the associated improved endothelial 
dysfunction is still to be further investigated. 
Longitudinal follow-up to determine patient-oriented 
CV outcome in correlation with FMD and serum 
visfatin is highly indicated. The long-term implications 
of vascular dysfunction should be the subject of 
further research. 
In conclusion, paediatric RTx recipients show 
lower serum visfatin level and better FMD than those 
on regular HD, reflecting less endothelial dysfunction 
and less cardiovascular risk. FMD in RTx recipients 
tends to be less than normal subjects while visfatin 
level of the same group is similar to controls. Pediatric 
RTx appears to have a positive impact on the growth 
development of children with ESRD. 
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